Yost S, Konal J L, Hoekstra A V
Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
Department of Obstetrics and Gynecology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
Gynecol Oncol Rep. 2019 Aug 7;29:89-93. doi: 10.1016/j.gore.2019.07.012. eCollection 2019 Aug.
Pegylated liposomal doxorubicin (PLD) is a palliative treatment option for patients with recurrent gynecologic malignancies. It has an appealing toxicity profile and responses can be prolonged. There is no consensus as to the level of cardiac toxicity. Current label warnings, National Comprehensive Cancer Network (NCCN) guidelines, and extrapolation of prescribing guidelines from doxorubicin, may limit PLD's use in patients with baseline cardiac comorbidities, limit the lifetime dosing of an effective palliative treatment, or lead to over-use of unnecessary cardiac testing. This case series describes the experience of 18 patients using prolonged courses of PLD for gynecologic malignancies with no cardiac toxicity.
聚乙二醇化脂质体阿霉素（PLD）是复发性妇科恶性肿瘤患者的一种姑息治疗选择。它具有吸引人的毒性特征，且缓解期可以延长。关于心脏毒性的程度尚无共识。目前的药品标签警告、美国国立综合癌症网络（NCCN）指南以及从阿霉素外推的处方指南，可能会限制PLD在有基线心脏合并症患者中的使用，限制一种有效姑息治疗的终身给药剂量，或者导致不必要的心脏检查过度使用。本病例系列描述了18例使用延长疗程的PLD治疗妇科恶性肿瘤且无心脏毒性的患者的经验。
